SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGooch & Housego Regulatory News (GHH)

Share Price Information for Gooch & Housego (GHH)

Share Price is delayed by 15 minutes
Get Live Data
992.00    44.00 (4.64%)
Bid:
972.00
Ask:
988.00
Spread: 16.00 (1.646%)
Market Cap: £271.52m
GHH Live PriceLast checked at - London Stock Exchange

Intraday Gooch & Housego Share Chart

Half Year Trading Update

7 Apr 2020 07:00

RNS Number : 9782I
Gooch & Housego PLC
07 April 2020
 

For immediate release

7 April 2020

 

 

Gooch & Housego PLC

("G&H" or the "Company")

 

Half Year Trading Update

 

Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of photonic components & systems, provides an update on trading in the six months to 31 March 2020.

Trading

Trading in the six months reflected trends that we have previously reported, including more recently an impact from the COVID-19 emergency.

Industrial laser demand remained at below 'normalised' levels, but orders for fibre optics, hi-reliability fibre couplers for undersea cables and our A&D and life science capabilities continued at a good level. In general we are now seeing improved demand from Japan, S.Korea and to an extent from China, but a push back of orders from some of our US and European customers.

Improved industrial laser demand will ultimately be driven by technical innovation such as 5G and new laser based manufacturing techniques. A&D and life sciences are more stable with areas of life sciences driving extra demand.

Overall trading in the first half of FY 2020, which was weighted more toward fibre optics, A&D and life sciences, is expected to have been lower than the same time prior year.

As at 31 March 2020 our order book was at £91.7 million (31 March 2019: £93.2 million), which represents a reduction on the same time last year of 1.7%, or 4.9% on a constant currency basis.

Priorities in the COVID-19 emergency

Our primary concern during the emergency is the health and safety of our staff, customers and suppliers. Wherever possible our employees are working from home and for those that need to work at our manufacturing sites we have implemented a range of new health and safety measures to ensure that we rigorously meet social distancing and cleanliness requirements and other relevant guidelines and regulations.

Our teams have been responsive and agile in the rapidly developing situation and we are working hard to ensure we continue to support our customers' products and programmes, many of which are classified as essential products and services.

Manufacturing capacity

As previously reported, four of our six manufacturing sites in the US are open as they are exempt from State wide 'stay at home' orders. The remaining two, Fremont and Cleveland are aiming to operate at around 50% of 'normal' capacity levels, which is an improvement on the temporary closures announced last month.

In the UK all of our five manufacturing sites are open though the unique nature of our Torquay facility is such that it will need to operate at a reduced capacity in order to rigorously adhere to the Government's COVID-19 guidelines. ITL is now operating at near to full capacity. This is due to increased demand for medical diagnostic kits and a unit which improves respiratory function and oxygen supply, as part of a ventilator system for patients in critical care, including those with COVID-19.

Cost control

Management has implemented a number of measures to control cash and costs. These measures are consistent with retaining a highly skilled workforce and maintaining the Group's infrastructure and capabilities to enable future growth post the COVID-19 emergency.

Financial strength

The Company remains in a good financial position with a strong balance sheet and good levels of available cash. We have recently completed an amendment to our existing credit facility, giving a total facility of $50 million until April 2023.

Outlook

It is uncertain how long the current COVID-19 emergency will last, but there is likely to be a material short term impact on G&H. We have previously indicated an expected increased H2 weighting to this year's trading performance, with the potential for revenue and profit to move into the Group's next financial year. A greater A&D and life science weighting is anticipated.

The Company is fundamentally sound and there is long term growth potential in each of our chosen sectors. We will continue to invest in novel, cutting edge photonic technologies. As such G&H remains well placed to take advantage of the recovery when it comes.

Mark Webster, Chief Executive Officer of Gooch & Housego, commented:

"Trading in the half year has continued along previously reported lines, including an impact from the COVID-19 emergency. Our order book remains at a good level for fibre optics, fibre couplers for undersea cables and A&D and life sciences.

"G&H is proud that in the US most of our product lines are considered to be vital for essential services and national security, enabling sites to stay open under 'stay at home orders'. In the UK all sites are open, albeit with Torquay operating at reduced capacity. We continue to manufacture critical components for industrial lasers, laser systems, telecom, A&D and life science products.

"We believe the current COVID-19 emergency has validated our long term strategy of diversification and moving up the value chain."

 

 

For further information contact: -

 

Mark Webster/Chris Jewell

Gooch & Housego PLC

01460 256440

Mark Court/ Charlotte Slater

Buchanan

020 7466 5000

Chris Baird/Patrick Robb/

David Anderson

Investec Bank plc

020 7597 5970

 

Notes to editors

 

1. Gooch & Housego is a photonics technology business headquartered in Ilminster, Somerset, UK with operations in the USA and Europe. A world leader in its field, the company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace & Defence, Industrial, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies.

 

2. All financial information included in this announcement is sourced from unaudited management accounts and excludes any specific items. This announcement contains certain forward-looking statements that are based on management's current expectations or beliefs as well as assumptions about future events. These are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which G&H operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results, and G&H's plans and objectives, to differ materially from those currently anticipated or implied in the forward-looking statements. Investors should not place undue reliance on any such statements. Nothing in this announcement should be construed as a profit forecast.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTVQLFBBZLEBBV
Date   Source Headline
3rd Jun 20267:00 amRNSDirectorate change
2nd Jun 20267:00 amRNSInterim Results
20th May 20267:00 amRNSNotice of Half Year Results
10th Apr 20262:25 pmRNSHolding(s) in Company
9th Apr 20267:00 amRNSHalf Year Trading Update
20th Mar 20263:16 pmRNSHolding(s) in Company
27th Feb 20262:23 pmRNSResult of AGM
27th Feb 20267:00 amRNSAGM Trading Update
2nd Feb 20267:00 amRNSChief Financial Officer appointment date
22nd Jan 20262:26 pmRNSHolding(s) in Company
13th Jan 20264:41 pmRNSHolding(s) in Company
12th Jan 20264:34 pmRNSPDMR notice
12th Jan 20263:30 pmRNSGrant of LTIP awards
9th Jan 20267:00 amRNSPDMR Notice and Issue of Equity
7th Jan 20267:00 amRNSPosting of Annual Report and Notice of AGM
12th Dec 20257:00 amRNSAppointment of Chief Financial Officer
2nd Dec 202511:36 amRNSDirector/PDMR Shareholding
2nd Dec 20257:00 amRNSResults for the year ended 30 September 2025
25th Nov 20257:00 amRNSNotification of Full Year Results
20th Nov 20252:14 pmRNSHolding(s) in Company
4th Nov 20257:07 amRNSDirectorate Update
8th Oct 20257:00 amRNSFurther Issue of Shares and TVR
7th Oct 20257:00 amRNSFull Year Trading Update
1st Oct 20252:15 pmRNSHolding(s) in Company
21st Jul 20257:00 amRNSChief Financial Officer Transition
15th Jul 20255:08 pmRNSHolding(s) in Company
30th Jun 20257:00 amRNSNotification of Major Holdings
23rd Jun 20252:30 pmRNSHolding(s) in Company - Replacement
20th Jun 202512:08 pmRNSHolding(s) in Company
18th Jun 20257:00 amRNSCompletion of Acquisition & Total Voting Rights
3rd Jun 20257:00 amRNSInterim Results
20th May 20257:00 amRNSNotification of Half Year Results
14th May 20257:00 amRNSAcquisition of Global Photonics
9th Apr 20252:16 pmRNSHolding(s) in Company
8th Apr 20257:00 amRNSHalf Year Trading Update
24th Feb 20252:19 pmRNSResult of AGM
24th Feb 20257:00 amRNSAGM Trading Update
7th Jan 20252:58 pmRNSGrant of LTIP Awards
6th Jan 202511:15 amRNSPosting of Annual Report and Notice of AGM
20th Dec 20243:15 pmRNSHolding(s) in Company
3rd Dec 20247:00 amRNSResults for the year ended 30 September 2024
4th Nov 20247:00 amRNSNotification of Full Year Results
30th Oct 20247:00 amRNSAcquisition of Phoenix Optical
28th Oct 20242:35 pmRNSHolding(s) in Company
8th Oct 20247:00 amRNSFull Year Trading Update
26th Sep 202410:31 amRNSDirector/PDMR Shareholding
23rd Aug 202412:52 pmRNSNotification of Major Holdings
16th Aug 20245:46 pmRNSHolding(s) in Company
16th Aug 20244:49 pmRNSHolding(s) in Company
15th Aug 20244:33 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.